About

Company description

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has the proven expertise, superior technologies and flexible solutions at the right scale to help ensure successful product development, launch, tech transfer and global reliable supply. Our team of nearly 13,000, including approximately 2,400 scientists at over 35 sites, develops more than 700 projects and helps launch over 200 products every year. We produce +72 billion doses of +7,000 products for more than 1,000 customers – or 1 in 20 doses taken by patients globally. We partner with 87 of the top 100 global pharmaceutical marketers, to 24 of 25 biological marketers, to 21 of 25 leading consumer health marketers, to thousands of small innovators globally. Our passion is to help unlock the full potential of your product.

More products better treatments reliably supplied ™


Quick facts

Sales markets Western Europe; Eastern Europe; Asia; Australia; North America; Central/South America
Affiliated categories: Analytical Development |Antibody Drug Conjugates (ADCs) |API Contract Manufacturing More

Upcoming events

9 sep 2020

CPhI North America 2020

9 - 11 Sep 2020 Philadelphia, USA Visit us at stand 1301 Book a meeting See our Exhibitor Profile   See full Exhibitor List
13 oct 2020

CPhI Worldwide 2020

13 - 15 October 2020 Milan, Italy Visit us at stand 2F10 Book a meeting See our Exhibitor Profile   See full Exhibitor List

Recently at

5 nov 2019

CPhI Worldwide 2019

5-7 November 2019 Frankfurt, Germany We were at stand 121A82 See our Exhibitor Profile   See full Exhibitor List
30 apr 2019

CPhI North America 2019

30 April - 2 May 2019 Chicago, USA We were at stand 1206 See our Exhibitor Profile   See full Exhibitor List

News about Catalent

Cambrex names Troy Player as head of early stage development and testing

31 Mar 2020

Cambrex names Troy Player as head of early stage development and testing

Cambrex has appointed pharma industry veteran, Troy Player, as president, early stage development and testing, the contract development and manufacturing organisation said Tuesday.

Read more

16 Mar 2020

Catalent partners with Biohaven on newly-approved fast-dissolve migraine treatment

The US Food and Drug Administration has approved migraine treatment Nurtec ODT, developed by Biohaven and using CDMO Catalent’s proprietary Zydis orally disintegrating tablet technology, the two firms said Monday.

Read more

26 Feb 2020

Perrigo, Catalent announce FDA approval of generic version of Teva’s ProAir HFA inhaler

A generic version of Teva’s ProAir HFA inhaler for asthma and chronic obstructive pulmonary disease has finally been approved by the US Food and Drug Administration, the partners in the project, Perrigo and Catalent, announced Tuesday.

Read more

11 Feb 2020

Catalent to manufacture first-in-class mAb targeting solid tumours

ZM008 could have potential benefits for the treatment of prostate cancer.

Read more